Zanvastro’s All-Ages Nod Rests on a Small Walking Trial

The U.S. Food and Drug Administration approved Zanvastro (zilganersen) on September 3, 2026, as the first drug that targets the protein buildup in Alexander disease. Ionis Pharmaceuticals got a label for babies, children, and adults after a study so small that most neurology programs would not run it as a pivotal trial.

The main win was walking speed in people 5 and older. The agency still wrote a disease-modifying indication with no age floor, and Ionis set a list price of $285,000 per dose.

The FDA Wrote an All-Ages Label From 54 Patients

Alexander disease is a GFAP astrocytopathy, a white-matter illness in which mutant glial fibrillary acidic protein clumps inside astrocytes as Rosenthal fibers. The FDA says it affects less than 1 in a million people and can bring seizures, lost motor skills, weak muscles, and rising pressure in the brain. Until this approval, care was supportive.

For patients with Alexander disease and their families, there have been no approved treatment options, only supportive care while the disease progresses. Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.

Emily Freilich, M.D., Director, Division of Neurology I, FDA Center for Drug Evaluation and Research

Ionis enrolled 54 people ages 1.5 to 53 across 13 sites in eight countries. The label describes a randomized main study of 49 patients 2 years and older plus an open-label group of 4 children younger than 2. Safety was tallied in 53. Because the illness is this scarce and hits at every age, reviewers assembled an indication covering infancy through adulthood.

For children under 2, the agency said direct controlled data were limited. Drug-level modeling found that a 50 mg dose should produce spinal-fluid exposure similar to older children, and the 4 treated infants supplied safety. That bridge, not a separate infant efficacy trial, is how babies got on the label. The decision landed 19 days before the September 22, 2026, PDUFA date and came with Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations, plus a priority review voucher.

Ionis called the nod its first independent launch from its neurology pipeline and its second independent launch of 2026. The company posted the news the same evening.

BREAKING NEWS: We’re proud to share that we have received U.S. FDA approval for ZANVASTRO™ (zilganersen), an important advance for patients and a meaningful milestone in our work to address serious neurological diseases. Read more: https://t.co/VQFBbFOEzf $IONS pic.twitter.com/3PNCAEslnK

— Ionis (@ionispharma) September 3, 2026

Outside biotech desks, the approval barely moved. The sharper reading is not the first-drug headline. It is how little controlled evidence sat under the youngest ages, and how quickly a 50 mg spinal dose became a commercial product.

THE PATH TO THE LABEL

1. October 1, 2024: FDA grants Fast Track for zilganersen, then still called ION373.
2. September 22, 2025: Ionis reports the pivotal walking-speed result and thanks 54 trial families.
3. December 2, 2025: Breakthrough Therapy designation follows the topline data.
4. March 2026: FDA accepts the new drug application for priority review.
5. June 2026: Recordati licenses rights outside the United States.
6. September 3, 2026: FDA approves Zanvastro for pediatric and adult patients.

Brett P. Monia, Ph.D., chief executive officer of Ionis, said the approval begins a new chapter for families who had faced a progressive, often fatal disease with no treatment options. The next chapter is whether hospitals can actually deliver a quarterly lumbar dose at the price Ionis posted.

Walking Speed Held While Younger Kids Climbed

The pivotal package is the Phase 1-3 study protocol coded NCT04849741. Patients 2 and older were randomized 2:1 to zilganersen or control every 12 weeks for 60 weeks, then everyone could enter open-label dosing. Two dose groups ran in the blinded phase: 25 mg in 8 people and 50 mg in 24, against 17 on control. Median age was 11. Mean baseline gait speed on the 10-meter walk test was 1.2 meters per second.

The primary analysis was not the full 50 mg arm. It was Stratum 1, people 5 and older with recent motor trouble, using prespecified imputation in 17 on Zanvastro 50 mg and 13 on control. Ionis called the gap statistically significant and clinically meaningful. The p-value was 0.041, which cleared the line with little room.

THE 61-WEEK MOTOR AND BIOMARKER GAP

The prescribing information states that gait speed fell 2.1 percent on drug and 35.4 percent on control. Treated walkers mostly held the line. They did not get faster. That is still a large split against untreated decline, and it is the number the approval rests on.

In the 2-to-4-year subgroup, walking speed is a poor yardstick, so investigators used Gross Motor Function Measure-88 dimensions for standing and for walking, running, and jumping. Four children on Zanvastro improved on that combined score. Three on control declined. Seven children total. Holly Kordasiewicz, Ionis’s chief development officer, said seeing some of that early motor development proceed, because the protein production had been turned down, was really exciting.

Secondary scores mostly leaned toward drug without matching the primary p-value. Patient global impression of change was an exception, with an odds ratio of 5.22 and a nominal p of 0.010. Serious adverse events were more common on control (47.1%) than on pooled zilganersen (37.5%). Amy Waldman, M.D., associate professor of neurology at the University of Pennsylvania, said the serious events were largely the disease itself, seizures and scoliosis among them, and that one patient who kept progressing in the blinded phase later died in open-label follow-up.

Jenny Pearson’s daughter Elise had her first seizure at 16 months, tried a long list of therapies, and then entered the zilganersen study. Pearson said the fog was being lifted on her brain, and her personality was getting a chance to come out. That is the toddler story the primary walk test never measured.

How Zanvastro Turns Down GFAP

Zilganersen is a GFAP-directed antisense oligonucleotide. It binds GFAP pre-mRNA, recruits RNase H, and cuts production of the protein that astrocytes overmake when the gene is mutated. The FDA’s phrasing is blunt: it reduces abnormal GFAP before more of it can pile up and do further harm.

That is a gain-of-function shutdown, not a gene edit and not a myelin transplant. Alexander disease is often filed under leukodystrophies because white matter falls apart, but the first broken cell is the astrocyte. Rosenthal fibers, the sticky GFAP-rich rods pathologists have known since W. Stewart Alexander’s 1949 case, sit in those cells. Dial the protein down and the hope is that astrocytes stop poisoning the circuits they are supposed to support.

Plasma GFAP dropped 33.6% versus control by week 61, which is the target-engagement mark regulators now expect from this class, after nusinersen in spinal muscular atrophy and tofersen in SOD1-ALS. The label does not claim that old injury is rebuilt. Walking still slipped 2.1% on the approved dose. For older patients, the offer is a slower slide. For the youngest, the GMFM-88 hint is that some skills can still be gained if the protein tap is closed while the brain is still wiring itself.

A Shot in the Spine Every Three Months

The approved dose is 50 mg into the spinal canal every 3 months, the same milligram amount from infancy through adulthood. A clinician who does lumbar punctures must give it, after diluting the drug with the artificial cerebrospinal fluid that ships in the carton. The vial holds 56 mg in 2.8 mL. Injection volume changes with age because spinal-fluid volume does.

INJECTION VOLUME BY AGE

The bolus runs over 1 to 3 minutes. Clinics may use sedation, local anesthetic, or imaging. A volume of the patient’s own spinal fluid roughly equal to the dose is removed first. Prepared syringes last 4 hours at room temperature or 24 hours in the refrigerator. There are no contraindications in the label. The boxed practical warning is aseptic meningitis.

One patient had a serious case in the blinded phase, had it again in open-label, needed a pause, and then got intravenous dexamethasone before later doses. White cells and protein in the spinal fluid kept rising even with steroid cover, but the patient stayed on drug without symptoms. Pleocytosis after the first 2 to 4 doses showed up in 7 of 24 people on 50 mg (29%) versus 3 of 17 on control (18%).

COMMON SIDE EFFECTS ON 50 MG VERSUS CONTROL

• Vomiting: 50% on Zanvastro 50 mg, 29% on control.
• Back pain: 50% versus 18%.
• Cough: 38% versus 18%.
• Headache: 29% versus 12%.
• Post-lumbar puncture syndrome: 29% versus 6%.
• Joint pain: 25% versus 6%.
• Throat pain: 21% versus 0%.
• Swallowing trouble: 17% versus 6%.

Those numbers are from 24 people on the approved dose and 17 on control, so each jump is a handful of patients. Thirty-eight people had received Zanvastro for a year at the safety cutoff, and 18 for two years. Median exposure was 60 weeks. Families should treat new meningitis-like symptoms as a reason to call, not as an expected hangover from a lumbar puncture.

Why Alexander Disease Is Easy to Miss

Most cases start before age 2. Infantile disease brings a large head, seizures, stiff limbs, delayed development, and vomiting. Juvenile and adult forms lean on speech and swallow problems, poor coordination, and autonomic trouble, and they are easier to file under more common diagnoses. MedlinePlus Genetics, in its page on the genetics of Alexander disease, notes that about 500 cases have been reported since 1949. Type I disease has a median life expectancy around 14.0 years. Later-onset type II is closer to 25.0 years.

HOW THE DISEASE SHOWS UP BY ONSET

• Neonatal: Seizures, hydrocephalus, severe motor and intellectual injury, often death within two years.
• Infantile (before age 4): Macrocephaly, seizures, spasticity, delayed development, failure to thrive.
• Juvenile and adult: Swallowing and speech failure, gait trouble, palatal myoclonus, autonomic symptoms, a slower course.

Ionis has said it has identified about 300 patients in the United States. The National Institutes of Health has put the U.S. count at fewer than 1,000. Both sit under the FDA’s less-than-1-in-a-million line. A UK Biobank analysis of GFAP variants found 106 carriers of pathogenic or likely pathogenic changes, about 1 in 4,435 people, and modeled later-onset disease at 6.8 per 100,000. That paper is not a patient registry, and it does not mean tens of thousands of Americans will line up for a lumbar antisense drug. It does mean adult Alexander disease has been hiding in bladder, airway, and psychiatric clinics, and a first approved drug will pull some of those people into genetic testing.

Every person in the pivotal study needed a clinical picture, a brain MRI, and a pathogenic GFAP variant. That triad is now the on-ramp to a $285,000 dose. Miss the gene test and there is no prescription.

$285,000 a Dose and a Voucher on the Side

Ionis priced Zanvastro at $285,000 per quarterly dose, which is $1,140,000 a year at list before rebates. Kyle Jenne, the company’s chief global product strategy officer, described a buy-and-bill path on the medical benefit, with coverage often going patient by patient as a medical exception. Ionis Every Step is the support desk for insurance paperwork, education, and copay help. The company has said eligible commercially insured patients may see out-of-pocket costs fall as low as zero. List price is still the number hospitals will see on the invoice.

THE U.S. LAUNCH MATH

• List price: $285,000 each dose, four doses a year at $1,140,000 before discounts.
• Known U.S. patients: About 300 identified by Ionis, with NIH putting the country under 1,000.
• Peak-sales view: Analyst Mitchell Kapoor has cited company guidance of more than $100 million, and a voucher that might fetch about $200 million if sold.
• Supply: Ionis said U.S. availability would follow in the coming weeks after the September 3, 2026, approval.

A first-in-disease ultra-orphan drug at that price will draw prior authorization, site-of-care limits, and a fight over who is “identified.” The quieter commercial asset is the rare pediatric disease voucher, which Ionis can use on a future filing or sell. Monia said the company’s first look is its wholly owned neurology stack, not a quick sale. In June 2026 Ionis licensed ex-U.S. rights to Recordati, which plans European and Japanese submissions in 2027.

That is the second-order payoff. Zanvastro is a small P&L line next to Ionis’s triglyceride and angioedema drugs. It is also the first time the company will detail, ship, and bill an intrathecal antisense medicine itself, after years of watching Biogen sell Spinraza. Behind it sit obudanersen for Angelman syndrome, already in Phase 3, and ION337 for Dravet syndrome, now in first-in-human dosing, plus earlier programs in Pelizaeus-Merzbacher disease and MECP2 duplication. The Alexander disease file is the rehearsal: a tiny randomized core, a biomarker drop, an age-bridge, a specialty lumbar network, and a six-figure dose.

Families who already know the GFAP result will be the first in line. The larger, slower work is finding the adults the textbooks never counted, and keeping infants on a quarterly spinal calendar long enough to see whether those GMFM-88 gains hold.

Frequently Asked Questions

Is Zanvastro a cure for Alexander disease?

No. The prescribing information describes treatment of Alexander disease, not reversal of injury already done. On the primary walk test, people 5 and older still lost 2.1% of gait speed over 61 weeks; the control group lost much more. Rosenthal fibers and white-matter damage that formed before the first dose are not claimed to clear.

How is Alexander disease diagnosed before a first dose?

The pivotal study required three things together: a clinical picture that fit, a brain MRI consistent with the disease, and a pathogenic variant in GFAP. That same triad is what specialists will use to justify coverage. A gene test alone, without imaging and symptoms, is not how the trial defined the illness.

Does Zanvastro have any contraindications?

The label lists none. Clinicians still have to screen for lumbar-puncture risks before each dose, and they are told to work up possible aseptic meningitis if fever, stiff neck, or photophobia appear. There are no adequate human pregnancy data; mouse work at up to 6 times the human dose on a body-surface-area basis did not show embryo-fetal harm.

What happens if a quarterly dose is missed?

Give the missed 50 mg as soon as possible, then count the next dose 3 months from that new date, not from the original calendar. The drug has no preservative, so a syringe mixed for a missed visit cannot be saved beyond the 4-hour room-temperature or 24-hour refrigerated window.

Will Zanvastro be sold outside the United States?

Not by Ionis. Recordati holds exclusive rights everywhere else and has said it is aiming for regulatory filings in Europe and Japan in 2027. The EMA already granted orphan designation to ION373, the development code, which does not by itself set a European timeline.

Disclaimer: This article is news reporting and analysis of an FDA approval and its trial data. It is for information only and is not medical advice, a treatment recommendation, or a substitute for care from a neurologist or other qualified clinician who knows a specific patient. Families considering Zanvastro should review the full prescribing information with that clinician, including lumbar-puncture risks, meningitis warning signs, and insurance rules, before any dose is scheduled. Figures, labels, prices, and availability described here reflect the FDA label, Ionis statements, and other sources as of the dates cited and may change as the launch proceeds.